Martinez 2012.

Methods	Twelve‐week randomised, open study
Participants	Outpatients fulfilling DSM‐IV criteria for Major Depressive Disorder (MDD), with a score of at least 16 on the Patient Health Questionnaire (PHQ‐9) at baseline and a score of at least 20 on Quick Inventory of Depression Syntomatology Self‐Report scale (QIDS‐SR) at visit 1 and 2. Exclusion criteria: pregnancy, lactation, absence of contraception. Patients taking an investigational drug (bupriopion, sertraline, venlafaxine, paroxetine, fluoxetine or escitalopram) were allowed to participated only if they had not adequately responded to treatment. Patients with a history of bipolar disorder, primary psychotic disorder, cognitive disorder or obsessive‐compulsive disorder, or current (within last 6 months) primary axis I diagnosis of panic disorder, post‐traumatic stress disorder, generalized anxiety disorder, social anxiety disorder, dysthymia, alcohol or eating disorders were excluded. To be at serious risk of suicide, the presence of a serious, unstable medical illness or clinically significant laboratories abnormality, dementia, mental retardation diagnosis, history of substance abuse or dependence within previous 6 months or positive urine drug screen for any substance of abuse, treatment with electroconvulsive therapy, initiation of psychotherapy within 6 weeks before study entry or during study participation were exclusion criteria.
Interventions	Fluoxetine: 57 participants Duloxetine: 372 participants Fluoxetine dose range: 20‐80 mg/day Duloxetine dose range: 30‐120 mg/day
Outcomes	Primary outcome: change in QIDS‐SR total score Secondary measures: Hamilton Rating Scale for Depression (HDRS)
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	High risk	Quote: "non‐blinded study"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "non‐blinded study"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "non‐blinded study"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number and reasons for discontinuation clearly reported. Endpoint mean score reported as a class
Selective reporting (reporting bias)	Unclear risk	Side effects reported only when occurred in more than 5% of the sample. Mean endpoint scores reported with standard deviation and denominator
Other bias	High risk	Quote: "funded by Lilly USA, Indianapolis", and this company produces fluoxetine